Brown, M.D., Regental Professor of the University of Texas System and Director of UT Southwestern's Erik Jonsson Center for Research in Molecular Genetics and Human Disease; John W. Creecy, CEO, Remeditex Ventures; David V. Goeddel, Ph.D., Managing Partner, The Column Group; Tim Kutzkey, Ph.D., Partner, The Column Group; and Brett A. Ringle, President, Remeditex Ventures. John A. Josey, Ph.D., former Vice President of Discovery Chemistry at Array BioPharma, Inc., will join Peloton as President and Chief Scientific Officer.
"Peloton's respected leadership team and focus on cutting-edge cancer biology, as well as its relationships with UT Southwestern and CPRIT, make it an attractive investment opportunity with significant value-creation potential. We are pleased to support the Company's ability to pursue its discovery and development goals," said David V. Goeddel, Ph.D., Managing Partner, The Column Group.
CPRIT (www.cprit.state.tx.us) focuses on expediting the innovation and commercialization of cancer research – in turn increasing the potential for a medical or scientific breakthrough – and enhancing access to evidence-based prevention programs and services. CPRIT accepts applications from Texas-based public and private entities for grants to support a wide variety of cancer-related research projects and for the delivery of cancer prevention programs and services.
"Peloton is an emblem of the emerging Texas-based biotechnology community, and CPRIT is delighted to contribute to its potential success in developing breakthrough cancer therapeutics and delivering significant value to cancer patients and their families. We anticipate a long and productive collaborative relationship," said Jerry Cobbs, CPRIT's Chief Commercialization Officer.
A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action.
Page: 1 2 3 Related biology technology :1
|SOURCE Peloton Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 20112
. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment3
. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics4
. Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics5
. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe6
. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination7
. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer8
. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases9
. Amicus Therapeutics Joins Russell 3000® Index10
. Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide11
. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement